H4R antagonist 1 is a highly selective histamine H4receptor (H4R) antagonist (IC50: 27 nM). H4R antagonist 1 does not show any noticeable binding affinity to other subtypes of histamine receptors, H1R, H2R, and H3R.
A-940894 is a histamine H4receptor antagonist with anti-inflammatory properties. A-940894 potently binds to both human and rat histamine H4receptors and exhibits considerably lower affinity for the human histamine H1, H2, or H3 receptors. A-940894 has g
VUF-10497 is a histamine H4receptor inverse agonist (pKi = 7.57). VUF-10497 was found to possess anti-inflammatory properties in vivo in the rat. VUF-10497 also possesses a considerable affinity for the human histamine H1 receptor.
JNJ-10191584, a potent and selective antagonist at the histamine H4receptor, has antiinflammatory and analgesic effects in animal studies of acute inflammation.
UR-PI376 is a histamine H4receptor agonist (hH4R agonist) (pEC50 = 7.47, alpha = 0.93), with low activity for hH1R and hH2R and significant selectivity for hH3R (pKB = 6.00, alpha =- 0.28), as in stable-use a membrane preparation of hH(x)R-expressing Sf9
Adriforant tartrate hydrate, also known as ZPL-3893787 tartrate hydrate, PF-3893787 tartrate hydrate and ZPL-389 tartrate hydrate, is a novel histamine H4receptor antagonist. Adriforant tartrate hydrate shows an excellent in vitro profile that warrants their further investigation in relevant models of human disease. Histamine H4receptor (H4R) has become a promising target for immuno-inflammatory diseases, such as allergic rhinitis, asthma or dermal allergies.